ArticlePharmaceutics2021
Development of Chitosan/Cyclodextrin Nanospheres for Levofloxacin Ocular Delivery.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Chitosan in Modern Pharmacotherapy: Chitosan Nanoparticles and Delivery Systems.Pharmaceutics · 2026Review
- Advantages of the Combined Use of Cyclodextrins and Chitosan in Drug Delivery: A Review.Pharmaceutics · 2026Review
- Topical Ocular Drug Delivery: The Impact of Permeation Enhancers.Pharmaceutics · 2025Review
- Advanced drug delivery systems for the management of local conditions.Therapeutic delivery · 2025Review
- Cyclodextrins: Enhancing Drug Delivery, Solubility and Bioavailability for Modern Therapeutics.Pharmaceutics · 2025Review
- Antimicrobial Preservatives in Cyclodextrin-Containing Drug Formulations.Pharmaceutics · 2024Review
- Study ofInternational journal of molecular sciences · 2024Article
- Review
- Formulation and Development of Nanofiber-Based Ophthalmic Insert for the Treatment of Bacterial Conjunctivitis.International journal of molecular sciences · 2024Article
- Advances in Cyclodextrins and Their Derivatives in Nano-Delivery Systems.Pharmaceutics · 2024Review
- Rutin/Sulfobutylether-β-Cyclodextrin as a Promising Therapeutic Formulation for Ocular Infection.Pharmaceutics · 2024Article
- Spanlastic-laden in situ gel as a promising approach for ocular delivery of Levofloxacin: In-vitro characterization, microbiological assessment, corneal permeability and in-vivo study.International journal of pharmaceutics: X · 2023Article
- Chitosan and Its Derivatives: Preparation and Antibacterial Properties.Materials (Basel, Switzerland) · 2023Review
- Combined System for the Simultaneous Delivery of Levofloxacin and Rifampicin: Structural and Functional Properties and Antibacterial Activity.Journal of functional biomaterials · 2023Article
- Chitosan: A Potential Biopolymer in Drug Delivery and Biomedical Applications.Pharmaceutics · 2023Review
- Bicalutamide Anticancer Activity Enhancement by Formulation of Soluble Inclusion Complexes with Cyclodextrins.Biomolecules · 2022Article
- Chitosan/Cyclodextrin Nanospheres for Potential Nose-to-Brain Targeting of Idebenone.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Cyclodextrin Inclusion Complexes with Antibiotics and Antibacterial Agents as Drug-Delivery Systems-A Pharmaceutical Perspective.Pharmaceutics · 2022Review
- Chitosan-Hyaluronan Nanoparticles for Vinblastine Sulfate Delivery: Characterization and Internalization Studies on K-562 Cells.Pharmaceutics · 2022Article
- Advances in Nanostructures for Antimicrobial Therapy.Materials (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Levofloxacin (LVF) is an antibacterial drug approved for the treatment of ocular infections. However, due to the low ocular bioavailability, high doses are needed, causing bacterial resistance. Polymeric nanospheres (NPs) loading antibiotic drugs represent the most promising approach to eradicate ocular infections and to treat pathogen resistance. In this study, we have developed chitosan NPs based on sulfobutyl-ether-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.